At the Kennedy Institute of Rheumatology in Oxford, Professor Tonia Vincent and her team have settled a decades-long scientific debate with a finding that could reshape how the world treats one of its most common diseases: osteoarthritis is not a collection of separate diseases, but a single condition with shared biological roots.
This breakthrough matters because osteoarthritis affects millions worldwide and remains one of the leading causes of disability. Yet despite its prevalence, no approved disease-modifying therapies exist—largely because researchers had been hunting for different cures to different "subtypes" that may never have existed. The STEpUP OA project, published in Nature Communications, represents the largest and most comprehensive molecular analysis of osteoarthritis tissue ever conducted, providing the scientific clarity the field has desperately needed.
The international collaboration, which brought together researchers from Europe, Canada, and the UK alongside industry and charity partners, analyzed synovial fluid—the lubricating fluid in the knee joint—from more than 1,300 people with established knee osteoarthritis. Using cutting-edge proteomics technology that measured more than 7,000 proteins per sample, the team compared molecular patterns to answer a fundamental question: is osteoarthritis truly one disease, or multiple distinct subtypes requiring different treatment approaches?
The answer was definitive. "We revealed no evidence of distinct disease subtypes," Vincent explained. "Instead, we've demonstrated that at the molecular level OA is a single disease with a common set of 'core' pathways, mostly related to tissue injury and repair." This clarity opens a new door. Rather than researchers pursuing separate treatments for phantom variants, they can now focus their efforts on shared biological mechanisms that affect all osteoarthritis patients.
Yet the study reveals something equally important: while osteoarthritis has a single molecular fingerprint, biological variation exists based on individual factors like age, sex, and body mass index. In participants with obesity, for example, the team observed additional inflammatory signals—not the immune cell–driven inflammation seen in rheumatoid arthritis, but a tissue-injury response likely linked to mechanical stress. Such variations explain why some patients progress faster or respond differently to therapies, knowledge that could help researchers design more targeted clinical trials and match individual patients to treatments more precisely.
Dr. Thomas Perry, the study's first author and a senior postdoctoral molecular epidemiologist at the Kennedy Institute, described the practical impact: "This work provides a clear map of the molecular landscape of OA and offers a valuable resource for researchers and pharmaceutical companies. It will allow us to match patients to therapies much more precisely—a crucial step towards developing long-awaited treatments that slow or halt disease progression."
The STEpUP OA dataset, now available to the research community, is expected to accelerate discovery across the field. Scientists can use it to explore key biological pathways, identify which patients are most likely to benefit from specific treatments, and design better-targeted clinical trials with lower costs and higher chances of success. For the millions living with osteoarthritis globally, this represents a turning point—from decades of fragmented research toward a unified, evidence-based path forward.